Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates PressReach · Aug 10, 2022
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast Cancer PressReach · Aug 10, 2022
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update PressReach · Aug 10, 2022
Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform PressReach · Aug 10, 2022
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier PressReach · Aug 10, 2022
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones PressReach · Aug 10, 2022
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination PressReach · Aug 9, 2022
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in Women PressReach · Aug 9, 2022
